SCHEMBL6010423

SCHEMBL6010423

COc1cc(-c2cccc(Cl)c2)c2cc(C(O)c3ccoc3)ccc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 3/20 0.38
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
NR1I3 Q14994 1/20 0.36
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
MAT2A P31153 1/20 0.33
CNR2 P34972 1/20 0.33
TACR3 P29371 1/20 0.33
EGFR P00533 1/20 0.32
NOTUM Q6P988 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
RORC P51449 2/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545656 0.80 LTB4R (0.38) LTB4RAURKAAURKBNR1I3JAK2
SCHEMBL6009561 0.79 FNTA (0.49) FNTAFNTB
SCHEMBL6010167 0.78 LTB4R (0.42) LTB4RAURKAAURKBNR1I3EGFR
SCHEMBL5657044 0.78 AURKA (0.35) LTB4RAURKAAURKBNR1I3CNR2
SCHEMBL1757872 0.74 MEN1 (0.49) LTB4RAURKAAURKBNR1I3MAT2A
SCHEMBL25652640 0.72 PTGS2 (0.35) LTB4RAURKAAURKBRORC
SCHEMBL13333684 0.72 LTB4R (0.37) LTB4RAURKAAURKBNR1I3MAT2A
SCHEMBL5545677 0.71 LTB4R (0.44) LTB4RAURKAAURKBNR1I3JAK2
SCHEMBL5656596 0.71 LTB4R (0.46) LTB4RAURKAAURKBNR1I3MAT2A
SCHEMBL25652623 0.71 PTGS2 (0.37) LTB4RNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067531-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-27 US disclosed
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives JANSSEN-CILAG S.A. (FR) 2003-10-23 US disclosed
EP-1322644-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024687-A1 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199547-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives FNTA, FNTB, RCE1 LTB4R 1779/4885AURKA 1346/4885AURKB 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.